3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Mesothelioma, Malignant
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Interventions
Pemetrexed
4
Cisplatin
4
tislelizumab
1
rilotumumab
1
regorafenib
1
pembrolizumab
1
defactinib
1
atezolizumab
1
Vorinostat
1
Trioxsalen
1
Tomography, Optical Coherence
1
Photochemotherapy
1
Paclitaxel
1
LMB-100
1
Gemcitabine
1
Dihematoporphyrin Ether
1
Cytoreduction Surgical Procedures
1
Cryotherapy
1
Carboplatin
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Mesothelioma, Malignant
×
tislelizumab
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn